Maine Overhauls Employer Substance Use Testing Law — Only a Medical Review Officer May Report a Confirmed Positive

Overview

Maine enacted LD 2110, "An Act to Update Employer Substance Use Testing Policy Requirements" (Public Law 2025, chapter 666), rewriting 26 MRSA §§681-683 for every employer that tests. A confirmed positive result may now be reported to an employer only by a medical review officer — a licensed physician who must act independently and hold clinical experience in controlled substance use disorders (§683, sub-§§7-A and 8, ¶E). The former "positive test result" is renamed "non-negative test result," and an applicant or employee must be given the opportunity to contest one by presenting a legitimate medical explanation to the MRO or confirmation laboratory before it is reported (§683, sub-§8, ¶B-1). The Act also confirms that Department of Labor authorization is required for any testing program and that an employer subject to federal testing requirements must test its non-federally-mandated employees in the same manner as its federally mandated ones. Employers governed by a federally mandated program — including DOT testing under the Omnibus Transportation Employee Testing Act — remain outside the subchapter under §681, sub-§8. (PL 2025, c. 666 / LD 2110)

This regulatory update carries high impact for employers in Maine. Below, we cover the key requirements, compliance timeline, practical implications, and recommended next steps.

Key Requirements

Requirements at a Glance

Key provisions of this regulatory update:

1. Maine enacted LD 2110, "An Act to Update Employer Substance Use Testing Policy Requirements" (Public Law 2025, chapter 666), rewriting 26 MRSA §§681-683 for every employer that tests
2. A confirmed positive result may now be reported to an employer only by a medical review officer — a licensed physician who must act independently and hold clinical experience in controlled substance use disorders (§683, sub-§§7-A and 8, ¶E)
3. The former "positive test result" is renamed "non-negative test result," and an applicant or employee must be given the opportunity to contest one by presenting a legitimate medical explanation to the MRO or confirmation laboratory before it is reported (§683, sub-§8, ¶B-1)
4. The Act also confirms that Department of Labor authorization is required for any testing program and that an employer subject to federal testing requirements must test its non-federally-mandated employees in the same manner as its federally mandated ones
5. Employers governed by a federally mandated program — including DOT testing under the Omnibus Transportation Employee Testing Act — remain outside the subchapter under §681, sub-§8

Compliance deadline: July 29, 2026

Who Is Affected and Where This Applies

This applies to employers operating in Maine (view Maine compliance profile).

Industries affected: healthcare, construction, manufacturing, transportation. This update is relevant across multiple sectors. Employers should assess applicability based on their specific workforce, operations, and regulatory exposure.

Compliance Timeline

Background and Context

The Drug Testing Regulatory Landscape

Workplace drug testing regulations have been evolving rapidly across the United States as states move to legalize or decriminalize cannabis. Federal law still classifies marijuana as a Schedule I controlled substance under the Controlled Substances Act, creating tension between state-level protections for off-duty cannabis use and federal workplace safety mandates — particularly for safety-sensitive positions governed by the Department of Transportation.

For employers, this patchwork means that drug testing policies compliant five years ago may now violate state law. The landscape is particularly complex for multi-state employers who must reconcile different rules for pre-employment, random, post-accident, and reasonable-suspicion testing. At the same time, federal agencies like FMCSA and the DOT maintain strict testing requirements that override state cannabis protections for regulated employees such as commercial drivers and pipeline workers.

Why This Matters for Employers

This is a high-impact regulatory change with broad implications. While this is specific to Maine, it reflects a regulatory trend that other states are likely to follow. Employers should not wait until the enforcement date to begin compliance planning — the time to assess your exposure and update your programs is now.

Cross-industry impact: This update affects employers across multiple sectors, including healthcare, construction, manufacturing, and transportation. Each industry may face different compliance burdens depending on their existing programs and workforce composition. Multi-site employers should coordinate their response across locations to ensure consistent compliance.

For HR directors, safety managers, and compliance officers, this update should trigger a review of current written programs, training records, and standard operating procedures. The cost of proactive compliance is almost always lower than the cost of responding to violations, litigation, or workplace incidents after the fact.

Penalties for Non-Compliance

Non-compliance with drug testing regulations creates financial exposure across multiple channels — from loss of federal contract eligibility under the Drug-Free Workplace Act to fines under 49 CFR Part 40 and state-level employee lawsuits for wrongful termination based on non-compliant testing.

What Employers Should Do Now

BlueHive provides drug testing services nationwide and tracks this topic through our Drug Testing compliance hub. View the Maine compliance profile for all tracked regulations in this state.

Frequently Asked Questions

Related Compliance Updates

• AB 2188: Pre-Employment Drug Testing Restrictions for Cannabis — Drug Testing, California (Jan 2024)
• Lawful Off-Duty Activities Protection — Drug Testing, Colorado (Jan 2024)
• BIPA Damages Clarification — Privacy, Illinois (Feb 2023)

---

Source: Official Legislation · Verified 2026-07-28

This article is part of BlueHive Compliance Watch, which monitors occupational health regulations across all 50 states and federal agencies. Browse all state profiles → · View all compliance articles →